RxDoctor Payments Data

Dina Kianoury

Critical Care Medicine · Washington, DCNPI 1891794053

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 71.5% of it on its own, with 7 other manufacturers making up the rest.

$4,635in general payments, 2019–2025

Across 46 payments — averaging $100.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$3K
  • Jazz Pharmaceuticals Inc.$367
  • Intuitive Surgical$276
  • Idorsia Pharmaceuticals US Inc$197
  • AstraZeneca$123
  • Amgen$123
  • plus $235 from 2 others

What the payments were for

  • Travel & lodging$1,79739%
  • Food & beverage$2,73959%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,635 in reported general payments places this provider in the 85th percentile of 59 critical care medicine providers in District of Columbia.

See all critical care medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$66,446
Medicare patients
318
Services billed
593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$75,925
XolairOmalizumab13$68,358
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$4,115
Arnuity ElliptaFluticasone Furoate12$3,113
Wixela InhubFluticasone Propion/Salmeterol14$2,264
Albuterol Sulfate HfaAlbuterol Sulfate31$1,339
Fluticasone Propionate39$489
Gabapentin81$404
Montelukast Sodium18$397
Trazodone Hcl21$159
Prednisone11$56
Azithromycin12$39

Paid to pharmacies, not to this prescriber.

Other critical care medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →